Phase I study of Vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks

Investigational New Drugs

Volumn 24, Issue 3, 2006, Pages 223-231

  Johnson, Peter ^a   Geldart, Thomas ^a   Fumoleau, Pierre ^b   Pinel, Marie Claire ^c   Nguyen, Laurent ^c   Judson, Ian ^d  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b CENTRE RENÉ GAUDUCHEAU   (France)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Phase I; Safety and toxicity; Vinflunine

Indexed keywords

NAVELBINE; VINCA ALKALOID; VINFLUNINE;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG DOSE REGIMEN; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; HUMAN; HYPOTENSION; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; TUMOR XENOGRAFT; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CONSTIPATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; VINBLASTINE;

EID: 33646681175     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-3902-0     Document Type: Article

References (19)

1. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, et al.: Randomized study of Vinorelbine and cisplatin versus vindesine and cisplatin versus Vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12(2): 360-7, 1994
2. Romero A, Rabinovich MG, Vallejo CT, Perez JE, Rodriguez R, Cuevas MA, et al.: Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 12(2): 336-41, 1994
3. Fahy JDA, Ribet JP, Jacquesy JC, Berrier C, Jouannetaud MP, F. Z. Vinca alkaloids in superacidic media: a method for creating a new family of antitumor derivatives. J Am Chem Soc 119(36): 8576-8577, 1997
4. Kruczynski A, Colpaert F, Tarayre JP, Mouillard P, Fahy J, Hill BT: Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol 41(6): 437-47, 1998
5. Hill BT, Fiebig HH, Waud WR, Poupon MF, Colpaert F, Kruczynski A: Superior in vivo experimental antitumour activity of vinflunine, relative to Vinorelbine, in a panel of human tumour xenografts. Eur J Cancer 35(3): 512-20, 1999
6. Kruczynski A, Barret JM, Etievant C, Colpaert F, Fahy J, Hill BT: Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol 55(5): 635-48, 1998
7. Ngan VK, Bellman K, Hill BT, Wilson L, Jordan MA: Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids Vinorelbine and its newer derivative vinflunine. Mol Pharmacol 60(1): 225-32, 2001
8. Ngan VK, Bellman K, Panda D, Hill BT, Jordan MA, Wilson L: Novel actions of the antitumor drugs vinflunine and Vinorelbine on microtubules. Cancer Res 60(18): 5045-51, 2000
9. Etiévant CKA, Chansard N, Cabrol N, Astruc J, Chazottes E, BT H: Characterization of apoptosis induced by vinflunine, a novel fluorinated vinca alkaloid, in sensitive and vinflunine resistant P388 tumor cells: concomitant cell cycle analysis. Proc Am Assoc Cancer Res 39: 166, 1998
10. Kruczynski A, Etievant C, Perrin D, Chansard N, Duflos A, Hill BT: Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development. Br J Cancer 86(1): 143-50, 2002
11. Pourroy B, Carre M, Honore S, Bourgarel-Rey V, Kruczynski A, Briand C, et al.: Low concentrations of vinflunine induce apoptosis in human SK-N-SH neuroblastoma cells through a postmitotic G1 arrest and a mitochondrial pathway. Mol Pharmacol 66(3): 580-91 2004
12. Etievant C, Barret JM, Kruczynski A, Perrin D, Hill BT: Vinflunine (20′,20′-difluoro-3′,4′-dihydroVinorelbine), anovel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Invest New Drugs 16(1): 3-17, 1998
13. Lobert S, Ingram JW, Hill BT, Correia JJ: A comparison of thermodynamic parameters for Vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol 53(5): 908-15, 1998
14. Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. DCTD, NCI, NIH, DHHS. March 1998
15. Bennouna J, Fumoleau P, Armand JP, Raymond E, Campone M, Delgado FM, et al. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol 14(4): 630-7, 2003
16. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment [WHO Offest Publication No. 48]. Geneva S, World Health Organization, 1979
17. Lang JR, Bolton S: A comprehensive method validation strategy for bioanalytical applications in the pharmaceutical industry-1. Experimental considerations. J Pharm Biomed Anal 9(5): 357-61, 1991
18. Lang JR, Bolton S: A comprehensive method validation strategy for bioanalytical applications in the pharmaceutical industry-2. Statistical analyses. J Pharm Biomed Anal 9(6): 435-42, 1991
19. US Department of Health and Human Services FaDACC. Guidance for Industry - Bioanalytical method validation. May 2001